Gilead's Descovy not worth the higher price over forthcoming Truvada generics: study

Bracing for generics to big-selling HIV prevention drug Truvada, Gilead Sciences is working to switch patients to its new option, Descovy. But the new med's additional benefits aren't worth the huge premium over cheap Truvada copies, researchers say.